4
Changes in Ownership
Nurix Therapeutics, Inc. Filed Acc 0001209191-21-059064
Chief Scientific Officer sold 400 shares at $29.92 ($11,968)
- Chief Scientific Officer acquired 400 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Hansen Gwenn · Chief Scientific Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2021-10-01 | Exercise or conversion : show line 1 in the form | +400 | $7.26 | $2,904 | 14,597 | D |
| 2021-10-01 | Sale : show line 2 in the form | −400 | $29.92 | $11,968 | 14,197 | D |
| Open-market sales · 400 sh · avg $29.92 · $11,968 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2021-10-01 | Exercise or conversion : show line 3 in the form Employee Stock Option (right to buy) | −400 | 69,066 | D |
Loading xslF345X03/doc4.xml…